These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Examination of α-exosite inhibitors against Botulinum neurotoxin A protease through structure-activity relationship studies of chicoric acid. Xue S; Seki H; Remes M; Šilhár P; Janda K Bioorg Med Chem Lett; 2017 Nov; 27(22):4956-4959. PubMed ID: 29050781 [TBL] [Abstract][Full Text] [Related]
10. Monoclonal Antibodies that Inhibit the Proteolytic Activity of Botulinum Neurotoxin Serotype/B. Fan Y; Dong J; Lou J; Wen W; Conrad F; Geren IN; Garcia-Rodriguez C; Smith TJ; Smith LA; Ho M; Pires-Alves M; Wilson BA; Marks JD Toxins (Basel); 2015 Aug; 7(9):3405-23. PubMed ID: 26343720 [TBL] [Abstract][Full Text] [Related]
12. Synthesis, Characterization, and in Vitro Anticancer Activity of Copper and Zinc Bis(Thiosemicarbazone) Complexes. Anjum R; Palanimuthu D; Kalinowski DS; Lewis W; Park KC; Kovacevic Z; Khan IU; Richardson DR Inorg Chem; 2019 Oct; 58(20):13709-13723. PubMed ID: 31339305 [TBL] [Abstract][Full Text] [Related]
13. Fully Human Monoclonal Antibodies Effectively Neutralizing Botulinum Neurotoxin Serotype B. Matsumura T; Amatsu S; Misaki R; Yutani M; Du A; Kohda T; Fujiyama K; Ikuta K; Fujinaga Y Toxins (Basel); 2020 May; 12(5):. PubMed ID: 32392791 [TBL] [Abstract][Full Text] [Related]
14. Botulinum neurotoxin inhibitor binding dynamics and kinetics relevant for drug design. Patel KB; Kononova O; Cai S; Barsegov V; Parmar VS; Kumar R; Singh BR Biochim Biophys Acta Gen Subj; 2021 Sep; 1865(9):129933. PubMed ID: 34023445 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of botulinum neurotoxin a protease inhibitors. Li B; Pai R; Cardinale SC; Butler MM; Peet NP; Moir DT; Bavari S; Bowlin TL J Med Chem; 2010 Mar; 53(5):2264-76. PubMed ID: 20155918 [TBL] [Abstract][Full Text] [Related]
16. Peptide inhibitors of botulinum neurotoxin serotype A: design, inhibition, cocrystal structures, structure-activity relationship and pharmacophore modeling. Kumar G; Kumaran D; Ahmed SA; Swaminathan S Acta Crystallogr D Biol Crystallogr; 2012 May; 68(Pt 5):511-20. PubMed ID: 22525749 [TBL] [Abstract][Full Text] [Related]
17. Epitope targeting of tertiary protein structure enables target-guided synthesis of a potent in-cell inhibitor of botulinum neurotoxin. Farrow B; Wong M; Malette J; Lai B; Deyle KM; Das S; Nag A; Agnew HD; Heath JR Angew Chem Int Ed Engl; 2015 Jun; 54(24):7114-9. PubMed ID: 25925721 [TBL] [Abstract][Full Text] [Related]
18. Interactions of a potent cyclic peptide inhibitor with the light chain of botulinum neurotoxin A: Insights from X-ray crystallography. Kumaran D; Adler M; Levit M; Krebs M; Sweeney R; Swaminathan S Bioorg Med Chem; 2015 Nov; 23(22):7264-73. PubMed ID: 26522088 [TBL] [Abstract][Full Text] [Related]
19. Computer-aided identification, synthesis, and biological evaluation of novel inhibitors for botulinum neurotoxin serotype A. Teng YH; Berger WT; Nesbitt NM; Kumar K; Balius TE; Rizzo RC; Tonge PJ; Ojima I; Swaminathan S Bioorg Med Chem; 2015 Sep; 23(17):5489-95. PubMed ID: 26275678 [TBL] [Abstract][Full Text] [Related]
20. The synthesis of 2,5-bis(4-amidinophenyl)thiophene derivatives providing submicromolar-range inhibition of the botulinum neurotoxin serotype A metalloprotease. Opsenica I; Filipovic V; Nuss JE; Gomba LM; Opsenica D; Burnett JC; Gussio R; Solaja BA; Bavari S Eur J Med Chem; 2012 Jul; 53():374-9. PubMed ID: 22516424 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]